CA2904433A1 - Non-oxidized, biological active parathyroid hormone determines mortality in hemodialysis patients - Google Patents

Non-oxidized, biological active parathyroid hormone determines mortality in hemodialysis patients Download PDF

Info

Publication number
CA2904433A1
CA2904433A1 CA2904433A CA2904433A CA2904433A1 CA 2904433 A1 CA2904433 A1 CA 2904433A1 CA 2904433 A CA2904433 A CA 2904433A CA 2904433 A CA2904433 A CA 2904433A CA 2904433 A1 CA2904433 A1 CA 2904433A1
Authority
CA
Canada
Prior art keywords
pth
oxidized
peptides
human pth
ipth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2904433A
Other languages
English (en)
French (fr)
Inventor
Franz Paul Armbruster
Berthold Hocher
Heinz Jurgen Roth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immundiagnostik AG
Original Assignee
Immundiagnostik AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immundiagnostik AG filed Critical Immundiagnostik AG
Publication of CA2904433A1 publication Critical patent/CA2904433A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2904433A 2013-03-08 2014-03-07 Non-oxidized, biological active parathyroid hormone determines mortality in hemodialysis patients Abandoned CA2904433A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13158401.3A EP2775306B1 (en) 2013-03-08 2013-03-08 Non-oxidized, biological active parathyroid hormone determines mortality in hemodialysis patients
EP13158401.3 2013-03-08
PCT/EP2014/054508 WO2014135701A1 (en) 2013-03-08 2014-03-07 Non-oxidized, biological active parathyroid hormone determines mortality in hemodialysis patients

Publications (1)

Publication Number Publication Date
CA2904433A1 true CA2904433A1 (en) 2014-09-12

Family

ID=47827083

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2904433A Abandoned CA2904433A1 (en) 2013-03-08 2014-03-07 Non-oxidized, biological active parathyroid hormone determines mortality in hemodialysis patients

Country Status (6)

Country Link
US (1) US10613101B2 (cg-RX-API-DMAC7.html)
EP (1) EP2775306B1 (cg-RX-API-DMAC7.html)
JP (1) JP6526577B2 (cg-RX-API-DMAC7.html)
CA (1) CA2904433A1 (cg-RX-API-DMAC7.html)
ES (1) ES2689193T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014135701A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2714565T3 (es) 2014-02-20 2019-05-29 Immundiagnostik Ag Diagnóstico in vitro y pronóstico de nefropatía inducida por contraste (nic) en pacientes sometidos a angiografía coronaria
EP3499235A1 (en) 2017-12-13 2019-06-19 Immundiagnostik AG Method of measuring auto-antibodies in bodily fluids
WO2019141791A1 (en) * 2018-01-17 2019-07-25 Immundiagnostik Ag Biomarker predicting coronary artery disease
ES2984718T3 (es) 2018-08-20 2024-10-30 Immundiagnostik Ag Composición de sorbente para el tratamiento preanalítico de muestras

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006596A1 (en) 1987-03-02 1988-09-07 Bissendorf Peptide Gmbh New cardiodilatin fragment, process for preparing same and use thereof
CA2040264A1 (en) 1990-04-12 1991-10-13 Tatsuhiko Kanmera Parathyroid hormone antagonists
DE4434551A1 (de) 1994-09-28 1996-04-04 Forssmann Wolf Georg Prof Dr D Peptide aus der Sequenz des hPTH (1-37)
US6689566B1 (en) 1999-01-14 2004-02-10 Scantibodies Laboratory, Inc. Methods, kits, and antibodies for detecting parathyroid hormone
DE19961350A1 (de) 1999-12-17 2001-06-21 Immundiagnostik Ag Verfahren zur Bestimmung der Parathormon-Aktivität in einer menschlichen Probe
DE10116552A1 (de) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
US20030082179A1 (en) 2001-07-03 2003-05-01 Hutchison James Scott Parathyroid hormone antibodies and related methods
EP2631247A1 (en) * 2012-02-22 2013-08-28 Immundiagnostik AG Means and methods of measuring parathyroid hormone in patients suffering from oxidative stress

Also Published As

Publication number Publication date
EP2775306A1 (en) 2014-09-10
JP2016512323A (ja) 2016-04-25
WO2014135701A1 (en) 2014-09-12
JP6526577B2 (ja) 2019-06-05
EP2775306B1 (en) 2018-06-27
ES2689193T3 (es) 2018-11-08
US10613101B2 (en) 2020-04-07
US20160025748A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
Kurpas et al. FGF23: a review of its role in mineral metabolism and renal and cardiovascular disease
Ebeling et al. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases
US9857382B2 (en) Assessing renal structural alterations and outcomes
DK2491401T3 (en) MCAM as a biomarker for fluid homeostasis
US8263351B2 (en) Diagnostic methods for congestive heart failure
Campostrini et al. Serum levels of the hepcidin-20 isoform in a large general population: The Val Borbera study
AU2003302132A1 (en) Bodily fluid markers of tissue hypoxia
US20190100576A1 (en) Signal biomarkers
US10613101B2 (en) Non-oxidized, biological active parathyroid hormone determines mortality in hemodialysis patients
US10317419B2 (en) Means and methods of measuring parathyroid hormone in patients suffering from oxidative stress
Yamashita et al. Serum osteocalcin levels are useful as a predictor of cardiovascular events in maintenance hemodialysis patients
EP2059818A2 (en) Biomarkers for pre-form of type 2 diabetes and methods for detecting the presence of absence of a pre-form of type 2 diabetes
Negrea Biochemical abnormalities in chronic kidney disease–mineral bone disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190301

FZDE Discontinued

Effective date: 20210909

FZDE Discontinued

Effective date: 20210909